Cargando…
Zonisamide effects on sleep problems and depressive symptoms in Parkinson’s disease
BACKGROUND: We aimed to evaluate the effect of zonisamide (ZNS) on motor symptoms and nonmotor symptoms such as depressive symptoms and sleep problems in Parkinson’s disease (PD) patients with or without tremor. METHODS: We conducted a 3‐month, open‐label study to assess the effects of ZNS on motor...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7994695/ https://www.ncbi.nlm.nih.gov/pubmed/33399276 http://dx.doi.org/10.1002/brb3.2026 |
_version_ | 1783669807668789248 |
---|---|
author | Suzuki, Keisuke Fujita, Hiroaki Matsubara, Takeo Haruyama, Yasuo Kadowaki, Taro Funakoshi, Kei Watanabe, Yuji Hirata, Koichi |
author_facet | Suzuki, Keisuke Fujita, Hiroaki Matsubara, Takeo Haruyama, Yasuo Kadowaki, Taro Funakoshi, Kei Watanabe, Yuji Hirata, Koichi |
author_sort | Suzuki, Keisuke |
collection | PubMed |
description | BACKGROUND: We aimed to evaluate the effect of zonisamide (ZNS) on motor symptoms and nonmotor symptoms such as depressive symptoms and sleep problems in Parkinson’s disease (PD) patients with or without tremor. METHODS: We conducted a 3‐month, open‐label study to assess the effects of ZNS on motor symptoms, depressive symptoms and sleep problems. Twenty levodopa‐treated PD patients with motor fluctuation completed the study. Patients received 25–50 mg/day of ZNS and were assessed for the Japanese version of the Movement Disorder Society Revision of the Unified PD Rating Scale (MDS‐UPDRS) parts I, III, and IV, PD Sleep Scale (PDSS)‐2, Beck depression inventory‐2 (BDI‐II), and PD Questionnaire (PDQ‐8) at baseline and after 1, 2 and 3 months of treatment. Patients were categorized into the tremor group and nontremor group to assess changes in clinical parameters. RESULTS: At 3 months, the scores on the MDS‐UPDRS parts I, III and IV significantly improved and off‐time reduced compared to baseline. Additionally, the PDSS‐2 total score significantly decreased at 3 months. Although there were no significant differences in changes in UPDRS part I, III, or IV between the groups after ZNS treatment, the tremor group had significant improvements in PDSS‐2 at 3 months and BDI‐II at 1, 2 and 3 months compared with the nontremor group. CONCLUSION: We showed the beneficial effects of ZNS on motor symptoms and sleep problems in levodopa‐treated PD patients with motor fluctuation. ZNS may be more effective for several nonmotor symptoms in PD patients with tremor compared with those without tremor. |
format | Online Article Text |
id | pubmed-7994695 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-79946952021-03-29 Zonisamide effects on sleep problems and depressive symptoms in Parkinson’s disease Suzuki, Keisuke Fujita, Hiroaki Matsubara, Takeo Haruyama, Yasuo Kadowaki, Taro Funakoshi, Kei Watanabe, Yuji Hirata, Koichi Brain Behav Original Research BACKGROUND: We aimed to evaluate the effect of zonisamide (ZNS) on motor symptoms and nonmotor symptoms such as depressive symptoms and sleep problems in Parkinson’s disease (PD) patients with or without tremor. METHODS: We conducted a 3‐month, open‐label study to assess the effects of ZNS on motor symptoms, depressive symptoms and sleep problems. Twenty levodopa‐treated PD patients with motor fluctuation completed the study. Patients received 25–50 mg/day of ZNS and were assessed for the Japanese version of the Movement Disorder Society Revision of the Unified PD Rating Scale (MDS‐UPDRS) parts I, III, and IV, PD Sleep Scale (PDSS)‐2, Beck depression inventory‐2 (BDI‐II), and PD Questionnaire (PDQ‐8) at baseline and after 1, 2 and 3 months of treatment. Patients were categorized into the tremor group and nontremor group to assess changes in clinical parameters. RESULTS: At 3 months, the scores on the MDS‐UPDRS parts I, III and IV significantly improved and off‐time reduced compared to baseline. Additionally, the PDSS‐2 total score significantly decreased at 3 months. Although there were no significant differences in changes in UPDRS part I, III, or IV between the groups after ZNS treatment, the tremor group had significant improvements in PDSS‐2 at 3 months and BDI‐II at 1, 2 and 3 months compared with the nontremor group. CONCLUSION: We showed the beneficial effects of ZNS on motor symptoms and sleep problems in levodopa‐treated PD patients with motor fluctuation. ZNS may be more effective for several nonmotor symptoms in PD patients with tremor compared with those without tremor. John Wiley and Sons Inc. 2021-01-05 /pmc/articles/PMC7994695/ /pubmed/33399276 http://dx.doi.org/10.1002/brb3.2026 Text en © 2021 The Authors. Brain and Behavior published by Wiley Periodicals LLC This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Research Suzuki, Keisuke Fujita, Hiroaki Matsubara, Takeo Haruyama, Yasuo Kadowaki, Taro Funakoshi, Kei Watanabe, Yuji Hirata, Koichi Zonisamide effects on sleep problems and depressive symptoms in Parkinson’s disease |
title | Zonisamide effects on sleep problems and depressive symptoms in Parkinson’s disease |
title_full | Zonisamide effects on sleep problems and depressive symptoms in Parkinson’s disease |
title_fullStr | Zonisamide effects on sleep problems and depressive symptoms in Parkinson’s disease |
title_full_unstemmed | Zonisamide effects on sleep problems and depressive symptoms in Parkinson’s disease |
title_short | Zonisamide effects on sleep problems and depressive symptoms in Parkinson’s disease |
title_sort | zonisamide effects on sleep problems and depressive symptoms in parkinson’s disease |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7994695/ https://www.ncbi.nlm.nih.gov/pubmed/33399276 http://dx.doi.org/10.1002/brb3.2026 |
work_keys_str_mv | AT suzukikeisuke zonisamideeffectsonsleepproblemsanddepressivesymptomsinparkinsonsdisease AT fujitahiroaki zonisamideeffectsonsleepproblemsanddepressivesymptomsinparkinsonsdisease AT matsubaratakeo zonisamideeffectsonsleepproblemsanddepressivesymptomsinparkinsonsdisease AT haruyamayasuo zonisamideeffectsonsleepproblemsanddepressivesymptomsinparkinsonsdisease AT kadowakitaro zonisamideeffectsonsleepproblemsanddepressivesymptomsinparkinsonsdisease AT funakoshikei zonisamideeffectsonsleepproblemsanddepressivesymptomsinparkinsonsdisease AT watanabeyuji zonisamideeffectsonsleepproblemsanddepressivesymptomsinparkinsonsdisease AT hiratakoichi zonisamideeffectsonsleepproblemsanddepressivesymptomsinparkinsonsdisease |